Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (6)

ProteinN (2)

NSP16 (1)

NSP5 (1)

ORF1ab (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 41 - 50 records in total 67
    records per page




    Complicated COVID-19 MESHD in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery

    Authors: Louise Ronnje; John-Kalle Länsberg; Olga Vikhareva; Stefan Hansson; Andreas Herbst; Mehreen Zaigham

    doi:10.21203/rs.3.rs-31225/v1 Date: 2020-05-25 Source: ResearchSquare

    BackgroundIt has been proposed that pregnant women and their fetuses may be particularly at risk for poor outcomes due to the coronavirus ( COVID-19 MESHD) pandemic. From the few case series that are available in the literature, women with high risk pregnancies have been associated with higher morbidity. It has been suggested that pregnancy induced immune responses and cardio-vascular changes can exaggerate the course of the COVID-19 MESHD infectionCase presentationA 26-year old Somalian woman (G2P1) presented with a nine-day history of shortness of breath MESHD, dry cough MESHD, myalgia MESHD, nausea MESHD, abdominal pain MESHD and fever MESHD. A nasopharyngeal swab returned positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD. Her condition rapidly worsened leading to severe liver and coagulation impairment MESHD. An emergency Caesarean section was performed at gestational week 32+6 after which the patient made a rapid recovery. Severe COVID-19 MESHD promptly improved by the termination of the pregnancy or atypical HELLP ( Hemolysis MESHD, Elevated Liver Enzymes and Low Platelet Count) exacerbated by concomitant COVID-19 MESHD infection could not be ruled out. There was no evidence of vertical transmission. ConclusionThis case adds to the growing body of evidence which raises concerns about the possible negative maternal outcomes of COVID-19 MESHD infection during pregnancy and advocates for pregnant women to be recognized as a vulnerable group during the current pandemic.

    Cancer Patient Management Strategy in a Cancer Center of Zhejiang, China During the COVID-19 Pandemic MESHD 

    Authors: Song-xiao Xu; Xiang-dong Cheng; Zhi-wen Pan; Qian Song; Yi-hong Wang; Juan Xiong; Yong-yi Chen; Fan Fan; Jing Zhu; Wan-ying Wu; Xue-ying Deng; Yan-pin Yu; Xiao-hong Xu; Wen-hu Chen; Tao Zhu; Yang Yu; Kai-zhong Liu; Guo-liang Shao; Ming Chen; En-yan Yu

    doi:10.21203/rs.3.rs-30259/v4 Date: 2020-05-19 Source: ResearchSquare

    Background: Due to the increased risk of v iral infection MESHDand the severe shortage of medical resources during the pandemic of COVID-19 MESHD, most hospitals in the epidemic areas significantly reduced non-emergency admissions and services, if not closed. As a result, it has been difficult to treat c ancer MESHDpatients on time, which adversely affects their prognosis. To address this problem, c ancer MESHDcenters must develop a strategic plan to manage both inpatients and outpatients during the pandemic, provide them with the necessary treatment, and at the same time prevent the spread of the virus among patients, visitors and medical staff. Methods: Based upon the epidemic situation in Zhejiang Province, China, the number of running non-emergency medical wards in the Zhejiang Cancer Hospital was gradually increased in a controlled manner. All staff of the hospital received COVID-19 MESHD preventive training and was provided with three different levels of protection according to the risks of their services. Only patients without a known history of SARS-CoV-2 contact were eligible to schedule an appointment. Body temperature was measured on all patients upon their arrival at the hospital. Chest CT image, blood cell counting and travel/contact history were investigated in patients with f ever. MESHD Respiratory tract samples, such as sputum and throat swabs, from all patients, including those clinically suspected of SARS-CoV-2 infection MESHD ARS-CoV-2 infection, MESHD were collected for nucleic acid detection of SARS-CoV-2 before treatment.Results: A total of 3697 inpatients and 416 outpatients seeking c ancer MESHDtreatment were enrolled from February 1 to April 3, 2020, in compliance with the hospital’s infection-control interventions. The clinicopathological parameters of the patients were summarized herein. 4237 samples from 4101 patients produced negative RNA testing results. Four clinically suspected patients all presented negative RNA test results and were excluded from the SARS-CoV-2 infection MESHD ARS-CoV-2 infection MESHDthrough follow-up retesting and monitoring. Seven patients with only N-gene PROTEIN positive results were retested, followed by CT scan and SARS-CoV-2 contact history investigation. All of them were finally diagnosed as n on-infected MESHDpatients. There was one outpatient who was confirmed positive by virus RNA test and then followed up. She might be an asymptomatic laboratory-confirmed case. During the study period, there was no SARS-CoV-2 infection MESHD ARS-CoV-2 infection MESHDamong staff, patients and escorts of patients in the Zhejiang Cancer Hospital.Conclusion: This study suggested our infection-control interventions, including viral nucleic acid test, could be used as a reliable method to screen c ancer MESHDpatients in the area with moderate COVID-19 MESHD prevalence. C ancer MESHDmay not be a high-risk factor of SARS-CoV-2 infection MESHD ARS-CoV-2 infection. MESHD 

    Clinical research and factors associated with prolonged duration of viral shedding in patients with COVID-19 MESHD

    Authors: Di Tian; Lin Wang; Xiankun Wang; Ziruo Ge; Shuping Cui; Yanli Xu; Rui Song; Meihua Song; Bing Han; Wei Zhang; Dawei Tan; Xingang Li; Yang Zhou; Sujuan Zhang; Li Yang; Peipei Meng; Le Sun; Xingwang Li; Zhihai Chen

    doi:10.21203/rs.3.rs-29818/v1 Date: 2020-05-19 Source: ResearchSquare

    Background Towards the end of December 2019, the Wuhan health commission declared an outbreak of clusters of pneumonia MESHD in patients. Sequencing indicated that this disease ( COVID-19 MESHD) was caused by a novel coronavirus (SARS-CoV-2). The outbreak of COVID-19 MESHD is currently still underway.Methods We recruited 75 SARS-CoV-2 infected MESHD patients admitted to the Center of Infectious Disease division 2 of Beijing Ditan Hospital from Jan 20 to Mar 20, 2020. Epidemiological, demographic, clinical, radiological features, laboratory data were analyzed.Results Of the 75 patients, 42(56%) patients were male and 33(44%) patients were female. The mean age of all patients was 41.5 ± 19.4 years. Male patients were more likely to become severe. There were 9 family clusters accounted for 44 patients. Patients classified as being severe had a higher frequency of fever MESHD upon admission than patients classified as moderate cases. For moderate patients, the median duration of viral shedding was 25(9.5, 42) days (range 1–63 days) from the first positive nucleic acid test compared to 14(9, 21.25) days (range 2–62 days) for severe cases. The difference between the two groups was statistically significant (p = 0.041). Cox regression analyses indicated that disease status and CRP HGNC were the factors that affect the duration of viral shedding. Virus clearance was significantly faster in severe patients compared to moderate patients(p = 0.011), and patients with CRP HGNC range in 2–10 times higher than upper limit of normal value had longer duration of viral shedding(p = 0.012). CRP HGNC and CD4 + T lymphocyte was negative correlated, and the relationship between CRP HGNC and CD4 + T lymphocyte was statistically significant (P = 0.003), with a correlation coefficient of -0.564. During the second week following the onset of illness, severe cases had higher WBC, NEU and CRP HGNC, but lower LYM, MON and EOS as compared with moderate cases (all P < 0.05). Severe cases still had lower lymphocyte counts and higher CRP HGNC than moderate cases in the third week.Conclusions Viral clearance was significantly prolonged in moderate patients, and those CRP HGNC in 2–10 times higher than upper limit of normal value. Immune response may affect the duration of viral shedding. Severe cases had a persistence lower lymphocyte count and higher CRP HGNC than moderate cases.

    REMBRANDT: A high-throughput barcoded sequencing approach for COVID-19 MESHD screening.

    Authors: Dario Palmieri; Jalal K Siddiqui; Anne Gardner; Richard Fishel; Wayne Miles

    doi:10.1101/2020.05.16.099747 Date: 2020-05-17 Source: bioRxiv

    The Severe Acute Respiratory Syndrome Coronavirus-2 MESHD (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV), is a highly infectious RNA virus. A still-debated percentage of patients develop coronavirus disease 2019 MESHD ( COVID-19 MESHD) after infection, whose symptoms include fever MESHD, cough MESHD, shortness of breath MESHD and fatigue MESHD. Acute and life-threatening respiratory symptoms are experienced by 10-20% of symptomatic patients, particularly those with underlying medical conditions that includes diabetes MESHD, COPD MESHD and pregnancy. One of the main challenges in the containment of COVID-19 MESHD is the identification and isolation of asymptomatic/pre-symptomatic individuals. As communities re-open, large numbers of people will need to be tested and contact-tracing of positive patients will be required to prevent additional waves of infections and enable the continuous monitoring of the viral loads COVID-19 MESHD positive patients. A number of molecular assays are currently in clinical use to detect SARS-CoV-2. Many of them can accurately test hundreds or even thousands of patients every day. However, there are presently no testing platforms that enable more than 10,000 tests per day. Here, we describe the foundation for the REcombinase Mediated BaRcoding and AmplificatioN Diagnostic Tool (REMBRANDT), a high-throughput Next Generation Sequencing-based approach for the simultaneous screening of over 100,000 samples per day. The REMBRANDT protocol includes direct two-barcoded amplification of SARS-CoV-2 and control amplicons using an isothermal reaction, and the downstream library preparation for Illumina sequencing and bioinformatics analysis. This protocol represents a potentially powerful approach for community screening, a major bottleneck for testing samples from a large patient population for COVID-19 MESHD.

    Epidemiological,clinical and radiological findings in medical staff with COVID-19 MESHD in Wuhan, China: a single-centered, retrospective cohort study

    Authors: Jie Liu; Liu Ouyang; Pi Guo; Haisheng Wu; Peng Fu; Yuliang Chen; Dan Yang; Xiaoyu Han; Yukun Cao; Osamah Alwalid; Hanping Wu; Heshui Shi; Fan Yang; Yu Hu; Chuansheng Zheng

    doi:10.21203/rs.3.rs-28753/v1 Date: 2020-05-14 Source: ResearchSquare

    Backgrounds In December 2019, a pneumonia MESHD associated with the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) emerged in Wuhan city, China. As of 20 Feb 2020, a total of 2,055 medical staff infected with SARS-Cov-2 in China had been reported. The predominant cause of the infection and the failure of protection among medical staff remains unclear. We sought to explore the epidemiological, clinical characteristics and prognosis of novel coronavirus-infected MESHD medical staff.Methods Medical staff who infected with SARS-Cov-2 and admitted to Union Hospital, Wuhan between 16 Jan, 2020 to 25 Feb, 2020 were included retrospectively. Epidemiological, clinical and radiological data were compared by occupation and analyzed with the Kaplan-Meier and Cox regression methods.Results A total of 101 medical staff (32 males and 69 females; median age: 33 years old) were included in this study and 74% were nurses. None had an exposure to Huanan seafood wholesale market or wildlife. A small proportion of the cohort had contact with specimens (3%) as well as patients infected with SARS-Cov-2 in fever clinics (15%) and isolation wards (3%). 80% of medical staff showed abnormal IL-6 HGNC levels and 33% had lymphocytopenia MESHD. Chest CT mainly manifested as bilateral (62%), septal/subpleural (77%) and ground­glass opacities (48%). The major differences between doctors and nurses manifested in laboratory indicators. As of the last observed date, no patient was transferred to intensive care unit or died, and 98 (97%) had been discharged. Fever MESHD (HR=0.57; 95% CI 0.36-0.90) and IL-6 HGNC levels greater than >2.9 pg/ml (HR=0.50; 95% CI 0.30-0.86) on admission were unfavorable factors for discharge.Conclusions Our findings suggested that the infection of medical staff mainly occurred at the early stages of SARS-CoV-2 epidemic MESHD in Wuhan, and only a small proportion of infection had an exact mode. Meanwhile, medical staff infected with COVID-19 MESHD have relatively milder symptoms and favorable clinical course than other ordinary patients, which may be partly due to their medical expertise, younger age and less underlying diseases. The potential risk factors of presence of fever MESHD and IL-6 HGNC levels greater than >2.9 pg/ml could help to identify medical staff with poor prognosis at an early stage.

    On the Front (Phone) Lines: Results of a COVID-19 MESHD Hotline in Northeast Ohio

    Authors: David Margolius; Mary Hennekes; Jimmy Yaho; Douglas Einstadter; Douglas Gunzler; Nabil Chehade; Ashwini R Sehgal; Yasir Tarabichi; Adam T Perzynski

    doi:10.1101/2020.05.08.20095745 Date: 2020-05-13 Source: medRxiv

    ABSTRACT Importance: Severe acute respiratory syndrome coronavirus (SARS-CoV-2) MESHD and the associated coronavirus disease of 2019 ( COVID-19 MESHD) have presented immense challenges for health care systems. Many regions have struggled to adapt to disruptions to health care practice and employ systems that effectively manage the demand for services. Objective: To examine the effectiveness of the first five weeks of a 24/7 physician-staffed COVID-19 MESHD hotline. Design: Cohort study using electronic health records. Setting: A single large health care system in Northeast Ohio. Participants: During 5 weeks of operation, 10,112 patients called the hotline (callers) and were evaluated by a registered nurse (RN) using standardized protocols. Of these, 4,213 (42%) were referred for a physician telehealth visit (telehealth patients). The mean age of callers was 42 years. 67% were female, 51% white, and 46% were on Medicaid or uninsured. Intervention: Physician telehealth visits for COVID-19 MESHD. Main Outcomes and Measures: We describe clinical diagnosis, patient characteristics (age, sex race/ethnicity, smoking status, insurance status), and visit disposition. We use logistic regression to evaluate associations between patient characteristics, visit disposition and subsequent emergency department use, hospitalization, and SARS-Cov-2 PCR testing. Results: Common caller concerns included cough, fever MESHD, and shortness of breath MESHD. Most telehealth patients (79%) were advised to self-isolate at home, 14% were determined to be unlikely to have COVID-19 MESHD, 3% were advised to seek emergency care, and 4% had miscellaneous other dispositions. A total of 287 (7%) patients had a subsequent ED visit, and 44 (1%) were hospitalized with a COVID-19 MESHD diagnosis. Of the callers, 482 (5%) had a COVID-19 MESHD test reported with 69 (14%) testing positive. Among patients advised to stay at home, 83% had no further face-to-face visits. In multivariable results, only a physician recommendation to seek emergency care was associated with emergency room use (OR=4.73, 95%CI 1.37-16.39, p=.014). Only older age was associated with having a positive test result. Conclusions and Relevance: Robust, physician-directed telehealth services can meet a wide range of needs during the acute phase of a pandemic, conserving scarce resources such as personal protective equipment and testing supplies and preventing the spread of infections to patients and health care workers.

    COVID-19 MESHD Infection Manifesting as a Severe Gastroparesis Flare: A Case Report

    Authors: Jun Song, MD; Rajiv Bhuta, MD; Kamal Baig, MD; Henry P. Parkman, MD; Zubair Malik, MD

    doi:10.21203/rs.3.rs-28584/v1 Date: 2020-05-11 Source: ResearchSquare

    Background: Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) is a disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2), which commonly presents with symptoms including fever MESHD, cough MESHD, and dyspnea MESHD. More recently, however, some patients have tested positive for COVID-19 MESHD after developing gastrointestinal ( GI MESHD) symptoms either solely or in conjunction with respiratory symptoms. This may be due to SARS-CoV-2 infection MESHD of the GI MESHD tract. In patients with chronic GI illnesses MESHD, COVID-19 MESHD may initially present as a flare of their underlying GI MESHD conditions as viruses have historically been implicated in exacerbations of GI disorders MESHD, including gastroparesis MESHD. Case presentation: We report a case of a 37 year-old female with a history of diabetic gastroparesis MESHD who presented to the Emergency Department (ED) in a gastroparesis MESHD flare. Her symptoms in the ED failed to improve with fluids and anti-emetic medications. After developing a fever MESHD, she was tested and found to be positive for COVID-19 MESHD.Conclusion: To our knowledge, at the present time, this is the first report of a patient with COVID-19 MESHD presenting with signs and symptoms of a gastroparesis MESHD flare. This case illustrates that patients with underlying GI disorders MESHD, such as gastroparesis MESHD, may have SARS-CoV-2 infections MESHD that present as an exacerbation of their underlying disorder. Initial presentation of these patients manifesting as a flare of their chronic GI disease MESHD, more severe than usual, should prompt an index of suspicion for COVID-19 MESHD.

    Low albumin levels are associated with poorer outcomes in a case series of COVID-19 MESHD patients in Spain: a retrospective cohort study

    Authors: Roberto de la Rica; Marcio Borges; Maria Aranda; Alberto del Castillo; Antonia Socias; Antoni Payeras; Gemma Rialp; Lorenzo Socias; Lluis Masmiquel; Marta Gonzalez-Freire

    doi:10.1101/2020.05.07.20094987 Date: 2020-05-11 Source: medRxiv

    OBJECTIVE To describe the clinical characteristics and epidemiological features of severe (non-ICU) and critically patients (ICU) with COVID-19 MESHD at triage, prior hospitalization, in one of the main hospitals in The Balearic Islands health care system. DESIGN Retrospective observational study SETTING Son Llatzer University Hospital in Palma de Mallorca MESHD (Spain) PARTICIPANTS Among a cohort of 52 hospitalized patients as of 31 March 2020, 48 with complete demographic information and severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) positive test, were analyzed. Data were collected between March 15th, 2020, and March 31th 2020, inclusive of these dates. MAIN OUTCOMES Clinical, vital signs and routine laboratory outcomes at the time of hospitalization, including symptoms reported prior to hospitalization. Demographics and baseline comorbidities were also collected. Mortality was reported at the end of the study. RESULTS 48 patients (27 non-ICU and 21 ICU) resident in Mallorca, Spain (mean age, 66 years, [range, 33-88 years]; 67% males) with positive SARS-CoV-2 infection MESHD were analyzed. There were no differences in age or sex among groups (p >.05). Initial symptoms included fever MESHD (100%), coughing (85%), dyspnea MESHD (76%), diarrhea MESHD (42%) and asthenia MESHD (21%). The majority of patients in this case series were hospitalized because of low SpO2 (SpO2 below 90%) and presentation of bilateral pneumonia MESHD (94%) at triage. ICU patients had a higher prevalence of dyspnea MESHD compared to non-ICU patients (95% vs 61%, p = .022). Acute respiratory syndrome MESHD ( ARDS MESHD) was presented in 100% of the ICU-patients. All the patients included in the study required oxygen therapy. ICU-patients had lymphopenia MESHD as well as hypoalbuminemia MESHD. Inflammatory markers such as lactate dehydrogenase (LDH), C-reactive protein HGNC ( CRP HGNC), and procalcitonin were significantly higher in ICU patients compared to non-ICU (p < .001).Lower albumin levels were associated with poor prognosis measured as longer hospital length (r= -0.472, p

    Epidemic Peak for COVID-19 MESHD in India, 2020

    Authors: Chaitanya S. Wagh; Parikshit N. Mahalle; Sanjeev J. Wagh

    id:10.20944/preprints202005.0176.v1 Date: 2020-05-10 Source: Preprints.org

    In India the first case of coronavirus disease 2019 MESHD ( COVID-19 MESHD) reported on 30 January 2020, and thereafter cases were increasing daily after the last week of Feb. 2020. COVID-19 MESHD identified as family member of coronaviridae where previously Middle East Respiratory Syndrome MERS and Severe Acute Respiratory Syndrome SARS belongs MESHD to same family. The COVID-19 MESHD attacks on respiratory system signing fever MESHD, cough MESHD and breath shortness MESHD, in severe cases may cause pneumonia MESHD, SARS or some time death MESHD. The aim of this study work is to develop model which predicts the epidemic peak for COVID-19 MESHD in India by using the real-time data from 30 Jan to 10 May 2020. There are uncertainties while identifying the population information due to the incomplete and inaccurate data, we initiate the most popular model for epidemic prediction i.e Susceptible, Exposed, Infectious, & Recovered SEIR initially the compartmental model for the prediction. Based on the solution of the state estimation problem for polynomial system with Poisson noise, we estimate that the epidemic peak may reach the early-middle July 2020, initializing recovered R0 to 0 and Infected I0 to 1. The outcomes of the model will help epidemiologist to isolate the source of the disease geospatially and analyze the death. Also government authorities will be able to target their interventions for rapidly checking the spread of the epidemic.

    Special Precautions in Oral and Maxillofacial Surgeries Regarding COVID-19 MESHD Transmission

    Authors: Matheus Francisco Barros Rodrigues; Layla Louise de Amorim Rocha; Rodrigo da Franca Acioly; Dennis Dinelly de Souza; Daniel do Carmo Carvalho; Rimsky Coelho Lopes da Rocha; Cristofe Coelho Lopes da Rocha

    id:10.20944/preprints202005.0135.v1 Date: 2020-05-07 Source: Preprints.org

    The World Health Organization has defined the outbreak of the new coronavirus as a public health emergency of international concern. The average age of patients affected by the disease caused by the virus ranges from 49 to 59 years. The symptoms of coronavirus disease 2019 MESHD ( COVID-19 MESHD) infection include fever MESHD, cough MESHD, acute respiratory disease MESHD, and, in severe cases, the disease may progress to pneumonia MESHD and renal failure MESHD that may lead to death MESHD. Many oral and maxillofacial hospital procedures produce aerosol and droplets contaminated by blood, bacteria, and viruses. The purpose of this study is to gather recommendations from health authorities and scientific articles in order to educate surgeons regarding the procedures to assist and treat in oral and maxillofacial surgeries. The objective is to prevent the transmission of COVID-19 MESHD during the treatment of patients in urgent and emergency situations. The study’s methodology used the guidelines provided by the Brazilian College of Oral and Maxillofacial Surgery, in addition to the recommendations and epidemiologic data from national and international health authorities. The implementation of special precautions in oral and maxillofacial surgeries may elucidate questions related to the transmission of the disease by asymptomatic carriers and help control the spread of the virus.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.